Bone loss after denosumab discontinuation is prevented by alendronate and zoledronic acid but not risedronate: a retrospective study

SUMMARY: A retrospective study of 121 patients who stopped denosumab (Dmab) then received no treatment (NT), risedronate (RIS), alendronate (ALN), or zoledronic acid (ZOL). Bone density (spine and hip) during and after Dmab discontinuation was measured. Treatment with ALN or ZOL, not NT and RIS, mit...

Descripción completa

Detalles Bibliográficos
Autores principales: Tutaworn, Teerapat, Nieves, Jeri W., Wang, Zhaorui, Levin, Justin E., Yoo, Jae E., Lane, Joseph M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813893/
https://www.ncbi.nlm.nih.gov/pubmed/36602607
http://dx.doi.org/10.1007/s00198-022-06648-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813893/
https://www.ncbi.nlm.nih.gov/pubmed/36602607
http://dx.doi.org/10.1007/s00198-022-06648-9

Ejemplares similares